| Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. | |
| | |
MedLine Citation:
|
PMID: 10573627 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Infection by certain human papillomaviruses (HPV), most notably HPV types 16 and 18, is the major risk factor for cervical cancer. Worldwide, this disease represents the second most frequent malignant tumor in women; thus, there is urgent need for efficient therapy and prevention. The natural history of cervical cancer and its precursors (cervical intraepithelial neoplasias), as well as animal experiments, strongly suggest that the immune system controls both the primary infection (by neutralizing antibodies directed against the major structural protein L1) and the progression of the disease (via cytotoxic T cells specific for the viral oncoproteins expressed in transformed cells, e.g., E7). By the expression of an HPV 16 L1E7 fusion protein, we have generated chimeric virus-like particles (CVLP). Immunization of mice with CVLPs induces neutralizing antibodies directed against L1 virus-like particles (devoid of the E7 portion) and E7-specific T cells as measured in vitro. Vaccinated animals are protected against tumor growth following inoculation of syngeneic HPV 16-transformed cells. In addition, we observed a therapeutic effect of vaccination on pre-existing tumors. This data allowed us to conclude that CVLPs are suitable for prevention and therapy of HPV infection. A vaccine based on HPV 16 L1E7 CVLPs is currently under development. |
| | |
Authors:
|
I Jochmus; K Schäfer; S Faath; M Müller; L Gissmann |
Related Documents
:
|
18797267 - Human papillomavirus vaccine and adolescents. 20138347 - Prevention strategies against human papillomavirus in males. 20113917 - Acceptability of human papillomavirus vaccine for males: a review of the literature. 18352847 - Therapeutic human papillomavirus vaccines: current clinical trials and future directions. 9529077 - Vaccination with plasmid dna encoding mycobacterial antigen 85a stimulates a cd4+ and c... 22300807 - Malaria's deadly secret: a skin stage. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Archives of medical research Volume: 30 ISSN: 0188-4409 ISO Abbreviation: Arch. Med. Res. Publication Date: 1999 Jul-Aug |
Date Detail:
|
Created Date: 2000-03-06 Completed Date: 2000-03-06 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9312706 Medline TA: Arch Med Res Country: MEXICO |
Other Details:
|
Languages: eng Pagination: 269-74 Citation Subset: IM |
Affiliation:
|
MediGene AG, Martinsried, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Female Humans Mice Papillomaviridae / immunology* Papillomavirus Infections / immunology, prevention & control*, virology Papillomavirus Vaccines* Tumor Virus Infections / immunology, prevention & control*, virology Vaccines, Synthetic / immunology* Viral Vaccines / immunology* Virion |
| Chemical | |
Reg. No./Substance:
|
0/Papillomavirus Vaccines; 0/Vaccines, Synthetic; 0/Viral Vaccines |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The ASL and hospitals: a model of emerging management
Next Document: Renal effects of experimental obstructive jaundice: morphological and functional assessment.